Opinion|Videos|August 5, 2024

Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

Author(s)Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center, Elizabeth Budde, MD, PhD, Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center

Episodes in this series

EP. 1 Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP. 1 Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

EP. 2 Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP. 2 Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP. 3 Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP. 3 Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP. 4 Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP. 4 Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP. 5 Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP. 5 Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP. 6 Panel Discuses Use of CD19 Bispecifics in Sequencing

EP. 6 Panel Discuses Use of CD19 Bispecifics in Sequencing

EP. 7 Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP. 7 Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP. 8 Current Approach to Bridging Therapy in R/R DLBCL

EP. 8 Current Approach to Bridging Therapy in R/R DLBCL

EP. 9 Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP. 9 Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP. 10 Management of CRS and ICANS with CAR T-cell Therapy

EP. 10 Management of CRS and ICANS with CAR T-cell Therapy

EP. 11 Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP. 11 Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP. 12 Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

EP. 12 Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

EP. 13 Bispecific therapy – treatment setting and management of short-term adverse events

EP. 13 Bispecific therapy – treatment setting and management of short-term adverse events

EP. 14 Bispecific therapy – management of long-term adverse events in the community setting

EP. 14 Bispecific therapy – management of long-term adverse events in the community setting

EP. 15 Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP. 15 Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP. 16 Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

EP. 16 Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

Please give an overview of treatment options for a patient who received 2L treatment with either CAR T-cell therapy or ASCT and has relapsed.
- What would be your treatment choice in the third line?
- What key issues do you consider in your sequencing decisions?
- Please discuss rationales for each:
Monoclonal antibody—tafasitamab?
ADC —loncastuximab, polatuzumab?
Would you go to CAR T after ASCT?
Bispecific antibody—epcoritamab or glofitamab?

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

MDS | Image Credit: © ArtificialHorizons - stock.adobe.com

September 21st, 2026

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.

Toon Van Gorp, MD, PhD

September 21st, 2026

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer

Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.

catalin - stock.adobe.com

September 21st, 2026

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.

Generic Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

September 21st, 2026

Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’

New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.

Elise A. Chong, MD

September 21st, 2026

Real-World Data Reinforce Liso-Cel Efficacy in R/R MCL

Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.

Brad S. Kahl, MD

September 21st, 2026

What Is the Current Role of Autologous Transplant in Mantle Cell Lymphoma?

Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD

September 21st, 2026

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.

The top 5 OncLive TV videos of the week cover insights in non–small cell lung cancer, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

September 20th, 2026

Five Under 5: Top Oncology Videos for the Week of 9/13

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

Trending on OncLive

CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care

Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications

FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS

Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma

NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer